Provectus Biopharmaceuticals announced the launch of VisiRose Inc., Provectus’s first Founded Entity. This new clinical-stage biotechnology company is focused on commercializing Rose Bengal Photodynamic Antimicrobial Therapy (“RB PDAT”) for the treatment of infectious keratitis and other serious eye infections using Provectus’s bioactive synthetic small molecule and active pharmaceutical ingredient (“API”) Rose Bengal Sodium (RBS), Provectus said in a press release.

RB PDAT, a non-invasive investigational treatment for eye infections, is based on ocular research from the Ophthalmic Biophysics Center at Bascom Palmer Eye Institute of the University’s Miller School of Medicine. RB PDAT combines a formulation of Provectus’s pharmaceutical-grade RBS API and OBC’s light-based medical device to treat eye infections caused by bacteria, fungi, and parasites, including multidrug-resistant organisms, the company said. The University of Miami is a minority equity shareholder of VisiRose.

The treatment has shown rapid infection resolution and improved patient outcomes in clinical trials across the United States, India, Brazil and Mexico.

Learn more about Rose Bengal Photodynamic Antimicrobial Therapy for infectious keratitis in the latest issue of Corneal Physician.